FI120154B - Rekombinant-DNA-virus, farmaceutisk sammansättning innehållande desamma, däggdjurcell, som är infekterad med desamma och implantat, som omfattar celler - Google Patents

Rekombinant-DNA-virus, farmaceutisk sammansättning innehållande desamma, däggdjurcell, som är infekterad med desamma och implantat, som omfattar celler Download PDF

Info

Publication number
FI120154B
FI120154B FI964784A FI964784A FI120154B FI 120154 B FI120154 B FI 120154B FI 964784 A FI964784 A FI 964784A FI 964784 A FI964784 A FI 964784A FI 120154 B FI120154 B FI 120154B
Authority
FI
Finland
Prior art keywords
virus
sequence
lpl
cell
cells
Prior art date
Application number
FI964784A
Other languages
English (en)
Finnish (fi)
Other versions
FI964784A0 (sv
FI964784A (sv
Inventor
Michel Perricaudet
Patrice Denefle
Patrick Benoit
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9463811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI120154(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of FI964784A0 publication Critical patent/FI964784A0/sv
Publication of FI964784A publication Critical patent/FI964784A/sv
Application granted granted Critical
Publication of FI120154B publication Critical patent/FI120154B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01034—Lipoprotein lipase (3.1.1.34)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (25)

1. Defekt rekomb inant-DNA-vi rus exklusive fagemid CDM8, vilket defekt rekombinant-DNA-virus omfattar en nuk- 5 leinsyrasekvens, soti i sin helhet eller delyis kodar lipo-proteinlipas (LPL) eller ett derivat därav.
2. Virus enligt patentkrav 1, kännetecknat av att DNA- s elevens en är en cDNA-sekvens .
3. Virus enligt patentkrav 1, kännetecknat av 10 att DNA-sekvensen är en gDNA-sekvens.
4. Virus enligt nägot av patentkraven 1 - 3, kännetecknat av att DNA-sekvensen kodar människans LPL.
5 Ad5 eller hunddjurens virustyp CAV-2.
14. Defekt rekombinant-DNA-adenovirus enligt patentkrav 12, som ytterligare omfattar en gen, som kodar apolipoprotein.
15. Virus enligt nägot av patentkraven 1 - 11, 10: kännetetknat av att det handlar om ett adenoassocie- rat virus
16. Virus enligt nägot av patentkraven 1 - 11, känneteeknat av att det handlar om ett retrovirus. 17. virus enligt nägot av patentkraven 1 - 11, 15 känne teeknat av att det handlar om ett herpesvirus (HSV).
18. Användning av ett virus enligt nägot av patentkraven 1 - 17 för framställning av en farmaeeutisk sananansättning, som är ävsedd för behandling och/eller fö- 20 rebyggande av patologien associerade med störningar i li-popro teinmetabol1smen.
19. Farmaeeutisk sammansä1.1ning, som omfattar ett eller fiera defekt rekombinant-DNA-virus enligt nägot av patentkraven 1 - 17. 25 20, Farmaeeutisk sammansättning enligt patentkrav 19, kännetecknad av att den är i en injekterbar form.
21. Farmaeeutisk sammansattning enligt patentkrav 19 eller 20, kännetecknad av att den omfattar 1Ö4 - 1014 pmy/ml, och företrädesvis 10° - 1010 pmy/inl, defekta 30 rekombinant-DNA-adenovirus.
22. Isolerad däggdjurscell, som är infekterad med ett eller fiera defekta rekombinant-DNA-virus enligt nägot av patentkraven 1 - 17.
23. Cell enligt patentkrav 22, kännetecknad 35 av att det handlar om en människocell. 36 24, implantat, som qmfattar celler enligt patentkrav 23, kännetecknat av att den extracellulära metrisen omfattar en gelningsföreriing, soin är företrädesvis vald bland kollagen, gelatin, glykosaminoglykaner, fibro- 5 nektin och lektiner,
25. Implantat, som omfattar ceiier enligt patentkrav 23 eller implantat enligt patentkrav 24, känne-tecknat -av att den extracel lulära mat risen ytterligare omfattar ett stöd, som möjliggör f'6rankring av inf@kterade 10 celler.
5. Virus enligt nägot av patentkraven 1-4, 15 kännetecknat av att DNA-sekvensen är placerad under kontroll av signaler, som möjliggör dess expression i in- fekterade celler.
6. Virus enligt patentkrav 5, kanne t e c kna t äv att expressionssignalerna väljs bland viruspromotorer. 2 0 7. Virus enligt patentkrav 6, kännetecknat av att egressions signal erna väljs bland promo tor erna ΒΙΑ, MLP, CMV och LTR-RSV.
8. Defekt rekombinant-DNA-virus, som omfattar en cDNA-sekvens, som kodar lipoproteiniipas under kontroll av 25 en promotor, som väljs bland LTR-RSV-prorrnotorn och CMV-ear ly-promotorn...
9, Virus enligt nägot av föregäende patentkrav, kännetecknat av att det omfattar en sekvens, som möjliggör lipoproteinlipasens orientering tili den infektera- 30 de cellens sekretiönsrutter.
10. Virus enligt patentkrav 9, k ä n n e t e c k n a t av att sekretionssekvensen är lipoproteinlipasens nativa sekvens.
11. Virus enligt nägot av patentkraven 1 - 10, 35 kännetecknat av att det är utan sinä genomomräden, vilka är erforderliga för dess replikation i mälcellen. 3 5 1:2.. Virus enligt nägot av patentkraven 1 - H, kannetecknat av att det handlar om ett adenovirus.
13. Virus enligt patentkrav 12, kannetecknat av att det handlar om mäimiskans adenovirustyp Ad2 eller
6. Implantat enligt patentkrav 2 5, karin e t e c k -nat av att stödet företrädesvis bestär av polytetrafluo-retylenfibrer.
FI964784A 1994-06-02 1996-11-29 Rekombinant-DNA-virus, farmaceutisk sammansättning innehållande desamma, däggdjurcell, som är infekterad med desamma och implantat, som omfattar celler FI120154B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9406759A FR2720756B1 (fr) 1994-06-02 1994-06-02 Virus recombinants, préparation et utilisation en thérapie génique.
FR9406759 1994-06-02
PCT/FR1995/000669 WO1995033840A1 (fr) 1994-06-02 1995-05-22 Virus recombinants, preparation et utilisation en therapie genique
FR9500669 1995-05-22

Publications (3)

Publication Number Publication Date
FI964784A0 FI964784A0 (sv) 1996-11-29
FI964784A FI964784A (sv) 1996-11-29
FI120154B true FI120154B (sv) 2009-07-15

Family

ID=9463811

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964784A FI120154B (sv) 1994-06-02 1996-11-29 Rekombinant-DNA-virus, farmaceutisk sammansättning innehållande desamma, däggdjurcell, som är infekterad med desamma och implantat, som omfattar celler

Country Status (14)

Country Link
US (1) US20130210898A1 (sv)
EP (1) EP0763116B2 (sv)
JP (1) JPH10500859A (sv)
AT (1) ATE248920T1 (sv)
AU (1) AU2620595A (sv)
CA (1) CA2190394C (sv)
DE (1) DE69531678T3 (sv)
FI (1) FI120154B (sv)
FR (1) FR2720756B1 (sv)
IL (1) IL113978A (sv)
MX (1) MX9605988A (sv)
NO (1) NO964894D0 (sv)
WO (1) WO1995033840A1 (sv)
ZA (1) ZA954386B (sv)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658729A (en) 1994-10-11 1997-08-19 The University Of British Columbia Method, reagent and kit for evaluating susceptibility to premature atherosclerosis
FR2720756B1 (fr) * 1994-06-02 1996-07-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US6814962B1 (en) * 1994-06-02 2004-11-09 Aventis Pharma S.A. Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000426A1 (en) * 1991-06-25 1993-01-07 Novo Nordisk A/S Mammalian pancreatic lipase and variant thereof
FR2720756B1 (fr) * 1994-06-02 1996-07-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
FR2749857B1 (fr) * 1996-06-12 1998-08-14 Centre Nat Rech Scient Generation de molecules replicatives in vivo

Also Published As

Publication number Publication date
EP0763116B2 (fr) 2008-04-23
AU2620595A (en) 1996-01-04
FI964784A0 (sv) 1996-11-29
IL113978A0 (en) 1995-10-31
CA2190394C (fr) 2008-10-14
NO964894L (no) 1996-11-18
ZA954386B (en) 1996-03-15
DE69531678D1 (de) 2003-10-09
FR2720756A1 (fr) 1995-12-08
EP0763116A1 (fr) 1997-03-19
MX9605988A (es) 1997-12-31
JPH10500859A (ja) 1998-01-27
FI964784A (sv) 1996-11-29
NO964894D0 (no) 1996-11-18
US20130210898A1 (en) 2013-08-15
DE69531678T2 (de) 2004-07-08
DE69531678T3 (de) 2009-01-29
FR2720756B1 (fr) 1996-07-12
ATE248920T1 (de) 2003-09-15
WO1995033840A1 (fr) 1995-12-14
EP0763116B1 (fr) 2003-09-03
CA2190394A1 (fr) 1995-12-14
IL113978A (en) 2006-06-11

Similar Documents

Publication Publication Date Title
US7008776B1 (en) Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
KR100330142B1 (ko) 재조합 바이러스 및 유전자 치료에서의 그의 사용
PT1200117E (pt) Tratamento à base de variantes da lipoproteína lipase
CZ291376B6 (cs) Varianty apolipoproteinu A-I a farmaceutická kompozice, která je obsahuje
ES2239367T3 (es) Polipeptidos llg de la familia de las triacilglicerol lipasas, y composiciones y metodos para su uso en la hidrolisis enzimatica y terapias proteicas y genicas.
KR19980703008A (ko) 레시틴-콜레스테롤 아실트랜스퍼라아제 발현 재조합바이러스 및 유전자 치료에 있어서의 이의 용도
FI120154B (sv) Rekombinant-DNA-virus, farmaceutisk sammansättning innehållande desamma, däggdjurcell, som är infekterad med desamma och implantat, som omfattar celler
JP2002536459A (ja) アテローム性動脈硬化症性病変の形成の阻害
JP2002514908A (ja) うっ血性心不全のための遺伝子治療
KR100403893B1 (ko) 글루타메이트 디 카르복실라제(gad) 활성을 암호화하는 재조합바이러스
Miyoshi et al. Gene delivery of paraoxonase-1 inhibits neointimal hyperplasia after arterial balloon-injury in rabbits fed a high-fat diet
JPWO2007139120A1 (ja) アミロイドβクリアランス促進剤
US20130164262A1 (en) Recombinant Viruses and their Use for Treatment of Atherosclerosis and Othe Forms of Coronary Artery Disease and Method, Reagent, and Kit for Evaluating Susceptibiity to Same
AU747449B2 (en) Recombinant viruses, preparation and use thereof in gene therapy
US20010039666A1 (en) Non-human mammalian model for atherosclerosis and methods for screening agents for use in the treatment of atherosclerosis
Nguyen The Cardioprotective Role of Prolyl Carboxypeptidase (PRCP) in Cardiac Hypertrophic Remodelling
Sarkar et al. Somatostatin gene transfer and expression in endothelial cells
Marvyn The suitability and consequence of renal tubule specific adipose triglyceride lipase ablation for the study of targeted lipid accumulation in the kidney
MXPA99004301A (es) Adenovirus recombinantes bicistronicos para el tratamiento de patologias relacionadas a las dislipoproteinemias
AU2928402A (en) Recombinant viruses coding for a glutamate decarboxylase (GAD) activity
UA75319C2 (uk) Виділений поліпептид, кодований геном, подібним до гена ліпази (llg), композиції, що його містять, та способи їх використання
KR20010029483A (ko) 울혈성 심부전을 위한 유전자 치료
AU4233499A (en) Recombinant viruses coding for a glutamate decarboxylase (GAD) activity
MXPA97006569A (es) Virus recombinantes que expresan la lecitina-colesterol aciltransferasa y sus usos en terapia genica

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: AVENTIS PHARMA S.A.

FG Patent granted

Ref document number: 120154

Country of ref document: FI

SPCF Supplementary protection certificate application filed

Spc suppl protection certif: C20130023

SPCG Supplementary protection certificate granted

Spc suppl protection certif: 400

Extension date: 20200522

MA Patent expired